Bremer, BirgitAnastasiou, Olympia E.Hardtke, SvenjaCaruntu, Florin AlexandruCurescu, Manuela G.Yalçın, KendalAkarca, Ulus S.Gürel, SelimZeuzem, StefanErhardt, AndreasLuth, StefanPapatheodoridis, George, V.Radu, MonicaIdilman, RamazanManns, Michael P.Cornberg, MarkusYurdaydın, CihanWedemeyer, Heiner2021-04-272021-04-272020Bremer, B., Anastasiou, O.E., Hardtke, S., Caruntu, F.A., Curescu, M.G., Yalçın, K. ve diğerleri. (2020). Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver International, 41(2), 295-299.1478-32231478-3231https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.14740https://hdl.handle.net/11468/6814WOS:000595714300001PMID: 33217778The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.eninfo:eu-repo/semantics/openAccessHDVHepatitis DPCRRelapseResidual viraemiaArticle412295299WOS:0005957143000012-s2.0-850970857633321777810.1111/liv.14740Q1Q2